SCHEMBL1335348

SCHEMBL1335348

CCOC(=O)c1ccccc1C=Cc1ccc(CN(C)C)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CAPN1 P07384 5/20 0.54
CTSB P07858 5/20 0.54
TSHR P16473 1/20 0.49
CTDSP1 Q9GZU7 1/20 0.46
HDAC3 O15379 1/20 0.46
HDAC6 Q9UBN7 1/20 0.46
CTSS P25774 2/20 0.45
CTSK P43235 2/20 0.45
ALDH1A1 P00352 1/20 0.43
HSD17B10 Q99714 1/20 0.43
BACE1 P56817 1/20 0.43
MMP13 P45452 1/20 0.41
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
ATM Q13315 1/20 0.40
MMP9 P14780 1/20 0.40
CTSL P07711 1/20 0.39
LMNA P02545 2/20 0.39
MAPT P10636 1/20 0.39
DHODH Q02127 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1335346 1.00 CAPN1 (0.54) CAPN1CTSBTSHRCTDSP1HDAC3
SCHEMBL27533745 0.84 TSHR (0.61) TSHRCTDSP1ALDH1A1HSD17B10BACE1
SCHEMBL7790064 0.84 TSHR (0.61) TSHRCTDSP1ALDH1A1HSD17B10BACE1
SCHEMBL1335174 0.83 CAPN1 (0.56) CAPN1CTSBTSHRHDAC3HDAC6
SCHEMBL1335172 0.83 CAPN1 (0.56) CAPN1CTSBTSHRHDAC3HDAC6
SCHEMBL7084226 0.82 CAPN1 (0.61) CAPN1CTSBTSHRHDAC3HDAC6
SCHEMBL1333103 0.81 CAPN1 (0.56) CAPN1CTSBTSHRHDAC3HDAC6
SCHEMBL1333100 0.81 CAPN1 (0.56) CAPN1CTSBTSHRHDAC3HDAC6
Dimethylamine SCHEMBL1335350 0.81 TSHR (0.53) TSHRCTDSP1ALDH1A1HSD17B10BACE1
SCHEMBL7664873 0.79 TSHR (0.54) TSHRCTDSP1ALDH1A1HSD17B10BACE1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110275615-A1 NOVEL SUBSTITUTED AMIDES, THEIR PREPARATION AND USE ABBVIE DEUTSCHLAND GMBH & CO KG (DE) 2011-11-10 US disclosed
US-7956093-B2 Substituted amides, their preparation and use ABBOTT GMBH & CO. KG (DE) 2011-06-07 US disclosed
US-20080113989-A1 For example, N-(1-Carbamoyl-1-oxo-3-phenylpropan-2-yl)-2-(E-2-(4-(1-pyrrolidinylmethyl)phenyl)ethen-1-yl)benzamide; calcium channel blockers; cardiovascular disorders; antiarthritic agents; inhibitors of enzymes, especially cysteine proteases such as calpain and cathepsins ABBVIE DEUTSCHLAND GMBH & CO KG (DE) 2008-05-15 US disclosed
US-7276500-B2 Calcium channel blockers; cardiovascular disorders; antiarthritic agents ABBOTT GMBH & CO. KG (DE) 2007-10-02 US disclosed
US-6753327-B1 NEURODEGENERATIVE DISORDER OR NEURONAL DAMAGE TREATMENT; INHIBITORS OF CALPAIN OR CATHEPSIN CYSTEINE PROTEASES; ANTIISCHEMIC AGENTS; REPERFUSION INJURIES ABBOTT GMBH & CO. KG (DE) 2004-06-22 US disclosed
US-20040082569-A1 Calcium channel blockers; cardiovascular disorders; antiarthritic agents ABBOTT GMBH & CO., KG 2004-04-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110275615-A1 NOVEL SUBSTITUTED AMIDES, THEIR PREPARATION AND USE CBR3, CBR1, HRH4 CAPN1 3398/4885CTSB 3328/4885TSHR 19/4885
US-20040082569-A1 Calcium channel blockers; cardiovascular disorders; antiarthritic agents CACNA1C, CACNA1E, RYR1 CAPN1 862/4885CTSB 2425/4885TSHR 657/4885
US-20080113989-A1 For example, N-(1-Carbamoyl-1-oxo-3-phenylpropan-2-yl)-2-(E-2-(4-(1-pyrrolidinylmethyl)phenyl)ethen-1-yl)benzamide; calcium channel blockers; cardiovascular disorders; antiarthritic agents; inhibitors of enzymes, especially cysteine proteases such as calpain and cathepsins CAPN1, CAPNS1, CAPN2 CAPN1 1/4885CTSB 10/4885TSHR 4029/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.